Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dbv Technologies SA is conducting a Phase 3 clinical study titled ‘A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy.’ The study aims to evaluate the 6-month safety of the DBV712 250 mcg patch in young children with peanut allergies, highlighting its potential significance in addressing this common and potentially severe allergy.
The intervention being tested is the DBV712 250 mcg patch, an epicutaneous system designed to deliver immunotherapy through the skin, helping to potentially desensitize children to peanut allergens.
The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is treatment-focused, aiming to provide a safe therapeutic option for peanut allergy in toddlers.
The study began on June 24, 2025, with its primary completion anticipated after the 6-month treatment period. The most recent update was submitted on July 18, 2025, indicating active recruitment and ongoing progress.
This study update could positively influence Dbv Technologies’ stock performance by reinforcing investor confidence in the company’s innovative approach to allergy treatment. It also positions the company competitively within the allergy therapeutics market, potentially impacting investor sentiment favorably.
The study is currently ongoing, with further details available on the ClinicalTrials portal.